Advertisement

Assessment of Generic Drugs in the Caribbean

  • 1 Citations

Abstract

In Caribbean countries the public sector is the largest purchaser of medicines. Patients may receive these medicines either at no cost or for very nominal charges at primary, secondary, or tertiary health care institutions. A limited drug list determined by the country’s experts or the national formulary influences decisions for purchase of medications. Patent rights on branded drugs are honored and generic equivalents are not purchased until patent expiry. Though cost-containment issues are forceful determinants of the selection of generic products, brand name products may be offered at more economical prices, as in Trinidad. Currently, approximately 35–55% of each country’s requirement is generic substitution; this is likely to increase. Bioavailability data are usually submitted while tendering for new introductions of generic products.

Standard bioavailability laboratories doing drug testing are not present in the region. The Caribbean Regional Drug Testing Laboratory in Jamaica undertakes analysis for Caribbean countries on government requests and for a fee for private consumers. Production of generic drugs in the English speaking Caribbean is undertaken predominantly in Barbados, Trinidad and Tobago, and Jamaica. Together with the eastern Caribbean countries they are the major buyers of generic products. Certification of the generic equivalent in the country of origin is mandatory. In Trinidad and Tobago the Minstry of Health is drafting a national drug policy which will address evaluation of generic substitutes. Concerns about the standards of generic equivalents from prescribers, regulatory authorities, and academia are discussed.

This is a preview of subscription content, log in to check access.

Access options

Buy single article

Instant unlimited access to the full article PDF.

US$ 39.95

Price includes VAT for USA

Subscribe to journal

Immediate online access to all issues from 2019. Subscription will auto renew annually.

US$ 189

This is the net price. Taxes to be calculated in checkout.

References

  1. 1.

    Alexander RE. Gage TW. Patient medication costs as a therapeutic consideration. J Am Dental Assoc. 1992; 123(7):191–196.

  2. 2.

    Fraser HS. Drug information issues: a Caribbean perspective. PAHO Bull. 1984;18:4:359–363.

  3. 3.

    Cruickshank JM. The cases for and against prescribing generic drugs: Don’t take innovative research based pharmaceutical companies for granted. Br Med J. 1988;297:1597–1598.

  4. 4.

    Turner P. Colaizzi JL, Eichelbaum M, Fourtillan JB, Mahon WA, Salva-Miguel JA. Generic bioequivalence. Lancet. 1987;ii: 517.

  5. 5.

    Collier J. The cases for and against prescribing generic drugs: generic prescribing benefits patients. Br Med J. 1988;297:596–597.

Download references

Author information

Correspondence to Lexley M. Pinto Pereira MBBS, MD.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Pereira, L.M.P., Fraser, H. & Burnett, F. Assessment of Generic Drugs in the Caribbean. Ther Innov Regul Sci 32, 145–150 (1998) doi:10.1177/009286159803200120

Download citation

Key Words

  • Generic products
  • Controls
  • Caribbean countries